This article first appeared on GuruFocus .
Release Date: May 18, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Strides Pharma Science Ltd ( BOM:532531 ) reported a consistent revenue growth with a CAGR of approximately 12% over the last three years.
-
The company achieved its highest ever EBITDA and operating PAT, with EBITDA margins expanding by 400 basis points to 19% in FY26.
-
Ex-US markets have shown robust growth, contributing nearly 50% of the revenue in Q4 FY26, marking a significant shift towards a diversified portfolio.
-
The company has significantly reduced its net debt to EBITDA ratio from 1.9x to 1.55x, reflecting strong cash generation and disciplined deleveraging.
-
Strides Pharma Science Ltd ( BOM:532531 ) has made strategic investments in R&D, focusing on medium and long-term growth, with expected benefits starting in the second half of FY27.
Negative Points
-
The US business faced challenges due to a weaker flu season and increased competition, impacting revenue growth.
-
There were delays in product launches and discontinuations in the US market, affecting the company's growth trajectory.
-
The company experienced increased costs in logistics and air freight, impacting EBITDA margins in Q4 FY26.
-
The geopolitical environment posed challenges, leading to cost pressures across raw materials, logistics, and foreign exchange.
-
The controlled substances segment faced lower-than-expected allocations due to being a new entrant, impacting near-term growth potential.
Q & A Highlights
Q: Can you provide insights into the current situation in the US market, especially regarding product discontinuations and launches? A: (Unidentified_3, MD and Group CEO) The US market faced challenges due to a weaker flu season and the need for a stable year of controlled substances before growth can resume. We have several product launches planned from the second half of this year through 2028. Our focus remains on maintaining profitability, and we anticipate growth to pick up from H2 onwards.
Q: How does the company plan to achieve its US revenue target of $375 to $400 million? A: (Unidentified_3, MD and Group CEO) We are committed to reaching our aspirational target of $375 to $400 million by leveraging drivers like nasal sprays and controlled substances. We are working diligently to achieve this growth trajectory.
Q: What is the impact of controlled substances on the company's margin trajectory? A: (Unidentified_3, MD and Group CEO) Controlled substances have a stringent regulatory process and require a past history for quota allocation. While they are expected to contribute to growth, the profitability is not expected to change dramatically due to controlled substances alone.
Q: Can you elaborate on the company's strategy for the ex-US markets? A: (Unidentified_3, MD and Group CEO) The ex-US markets have shown strong growth, with a CAGR of around 19% over the last three years. We are focusing on building a high-quality, sustainable business with stable pricing and strong partner relationships. The Sandoz acquisition will further strengthen our presence in Africa.
Q: What are the company's plans for R&D investments and new product filings? A: (Unidentified_3, MD and Group CEO) We plan to invest $20 to $25 million in R&D over the next two years, focusing on growth engines like nasal sprays, transdermal patches, and films. We expect to start filing for these products in the next 12 to 18 months, with commercialization expected beyond FY28.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
